Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder

Dan V. Iosifescu, Nicoletta Clementi-Craven, Renerio Fraguas, George I. Papakostas, Timothy Petersen, Jonathan E. Alpert, Andrew A. Nierenberg, Maurizio Fava

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Objective: An increased association between depression and cardiovascular disease, as well as cardiovascular risk factors, led to the "vascular depression" hypothesis. This subtype of depression is postulated to have a different clinical presentation and to be more treatment-resistant. In this study, we measured the impact of cardiovascular risk factors on the outcome of antidepressant treatment in major depressive disorder (MDD). Method: We enrolled 348 MDD subjects, ages 19 to 65 years, in an 8-week treatment study with 20 mg fluoxetine per day. We recorded for each subject 6 cardiovascular risk factors: age (male ≥45, female ≥55), smoking, family history, hypertension, diabetes, hypercholesterolemia; and we defined a cardiovascular risk score (range, 0-6) by the number of risk factors present. Treatment outcome was measured as response (≥50% improvement on the 17-item Hamilton Rating Scale for Depression [Ham-D-17]) and remission (final Ham-D-17≤7). Results: In logistic regression analyses, the cardiovascular risk score was significantly associated with treatment nonresponse and lack of remission when adjusting for age of onset of MDD and baseline severity of depression. The cardiovascular risk score remained significantly associated with treatment nonresponse when we additionally controlled for overall medical burden (measured with the Cumulative Illness Rating Scale). Among individual cardiovascular risk factors, elevated total cholesterol was a significant predictor of treatment nonresponse and lack of remission. Conclusion: Cardiovascular risk factors may have negative effects on the course of treatment in MDD. These results support the concept of "vascular depression" in younger subjects.

Original languageEnglish (US)
Pages (from-to)703-706
Number of pages4
JournalPsychosomatic Medicine
Volume67
Issue number5
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Major Depressive Disorder
Pharmacology
Depression
Hypercholesterolemia
Blood Vessels
Fluoxetine
Age of Onset
Antidepressive Agents
Cardiovascular Diseases
Logistic Models
Smoking
Regression Analysis
Hypertension

Keywords

  • Cardiovascular risk factors
  • Major depressive disorder
  • Treatment outcome

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)

Cite this

Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. / Iosifescu, Dan V.; Clementi-Craven, Nicoletta; Fraguas, Renerio; Papakostas, George I.; Petersen, Timothy; Alpert, Jonathan E.; Nierenberg, Andrew A.; Fava, Maurizio.

In: Psychosomatic Medicine, Vol. 67, No. 5, 09.2005, p. 703-706.

Research output: Contribution to journalArticle

Iosifescu, DV, Clementi-Craven, N, Fraguas, R, Papakostas, GI, Petersen, T, Alpert, JE, Nierenberg, AA & Fava, M 2005, 'Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder', Psychosomatic Medicine, vol. 67, no. 5, pp. 703-706. https://doi.org/10.1097/01.psy.0000170338.75346.d0
Iosifescu, Dan V. ; Clementi-Craven, Nicoletta ; Fraguas, Renerio ; Papakostas, George I. ; Petersen, Timothy ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Fava, Maurizio. / Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. In: Psychosomatic Medicine. 2005 ; Vol. 67, No. 5. pp. 703-706.
@article{eb9a681ffa09415b8a674cf66238ce44,
title = "Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder",
abstract = "Objective: An increased association between depression and cardiovascular disease, as well as cardiovascular risk factors, led to the {"}vascular depression{"} hypothesis. This subtype of depression is postulated to have a different clinical presentation and to be more treatment-resistant. In this study, we measured the impact of cardiovascular risk factors on the outcome of antidepressant treatment in major depressive disorder (MDD). Method: We enrolled 348 MDD subjects, ages 19 to 65 years, in an 8-week treatment study with 20 mg fluoxetine per day. We recorded for each subject 6 cardiovascular risk factors: age (male ≥45, female ≥55), smoking, family history, hypertension, diabetes, hypercholesterolemia; and we defined a cardiovascular risk score (range, 0-6) by the number of risk factors present. Treatment outcome was measured as response (≥50{\%} improvement on the 17-item Hamilton Rating Scale for Depression [Ham-D-17]) and remission (final Ham-D-17≤7). Results: In logistic regression analyses, the cardiovascular risk score was significantly associated with treatment nonresponse and lack of remission when adjusting for age of onset of MDD and baseline severity of depression. The cardiovascular risk score remained significantly associated with treatment nonresponse when we additionally controlled for overall medical burden (measured with the Cumulative Illness Rating Scale). Among individual cardiovascular risk factors, elevated total cholesterol was a significant predictor of treatment nonresponse and lack of remission. Conclusion: Cardiovascular risk factors may have negative effects on the course of treatment in MDD. These results support the concept of {"}vascular depression{"} in younger subjects.",
keywords = "Cardiovascular risk factors, Major depressive disorder, Treatment outcome",
author = "Iosifescu, {Dan V.} and Nicoletta Clementi-Craven and Renerio Fraguas and Papakostas, {George I.} and Timothy Petersen and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Maurizio Fava",
year = "2005",
month = "9",
doi = "10.1097/01.psy.0000170338.75346.d0",
language = "English (US)",
volume = "67",
pages = "703--706",
journal = "Psychosomatic Medicine",
issn = "0033-3174",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder

AU - Iosifescu, Dan V.

AU - Clementi-Craven, Nicoletta

AU - Fraguas, Renerio

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Fava, Maurizio

PY - 2005/9

Y1 - 2005/9

N2 - Objective: An increased association between depression and cardiovascular disease, as well as cardiovascular risk factors, led to the "vascular depression" hypothesis. This subtype of depression is postulated to have a different clinical presentation and to be more treatment-resistant. In this study, we measured the impact of cardiovascular risk factors on the outcome of antidepressant treatment in major depressive disorder (MDD). Method: We enrolled 348 MDD subjects, ages 19 to 65 years, in an 8-week treatment study with 20 mg fluoxetine per day. We recorded for each subject 6 cardiovascular risk factors: age (male ≥45, female ≥55), smoking, family history, hypertension, diabetes, hypercholesterolemia; and we defined a cardiovascular risk score (range, 0-6) by the number of risk factors present. Treatment outcome was measured as response (≥50% improvement on the 17-item Hamilton Rating Scale for Depression [Ham-D-17]) and remission (final Ham-D-17≤7). Results: In logistic regression analyses, the cardiovascular risk score was significantly associated with treatment nonresponse and lack of remission when adjusting for age of onset of MDD and baseline severity of depression. The cardiovascular risk score remained significantly associated with treatment nonresponse when we additionally controlled for overall medical burden (measured with the Cumulative Illness Rating Scale). Among individual cardiovascular risk factors, elevated total cholesterol was a significant predictor of treatment nonresponse and lack of remission. Conclusion: Cardiovascular risk factors may have negative effects on the course of treatment in MDD. These results support the concept of "vascular depression" in younger subjects.

AB - Objective: An increased association between depression and cardiovascular disease, as well as cardiovascular risk factors, led to the "vascular depression" hypothesis. This subtype of depression is postulated to have a different clinical presentation and to be more treatment-resistant. In this study, we measured the impact of cardiovascular risk factors on the outcome of antidepressant treatment in major depressive disorder (MDD). Method: We enrolled 348 MDD subjects, ages 19 to 65 years, in an 8-week treatment study with 20 mg fluoxetine per day. We recorded for each subject 6 cardiovascular risk factors: age (male ≥45, female ≥55), smoking, family history, hypertension, diabetes, hypercholesterolemia; and we defined a cardiovascular risk score (range, 0-6) by the number of risk factors present. Treatment outcome was measured as response (≥50% improvement on the 17-item Hamilton Rating Scale for Depression [Ham-D-17]) and remission (final Ham-D-17≤7). Results: In logistic regression analyses, the cardiovascular risk score was significantly associated with treatment nonresponse and lack of remission when adjusting for age of onset of MDD and baseline severity of depression. The cardiovascular risk score remained significantly associated with treatment nonresponse when we additionally controlled for overall medical burden (measured with the Cumulative Illness Rating Scale). Among individual cardiovascular risk factors, elevated total cholesterol was a significant predictor of treatment nonresponse and lack of remission. Conclusion: Cardiovascular risk factors may have negative effects on the course of treatment in MDD. These results support the concept of "vascular depression" in younger subjects.

KW - Cardiovascular risk factors

KW - Major depressive disorder

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=25844477455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844477455&partnerID=8YFLogxK

U2 - 10.1097/01.psy.0000170338.75346.d0

DO - 10.1097/01.psy.0000170338.75346.d0

M3 - Article

C2 - 16204427

AN - SCOPUS:25844477455

VL - 67

SP - 703

EP - 706

JO - Psychosomatic Medicine

JF - Psychosomatic Medicine

SN - 0033-3174

IS - 5

ER -